Table 1 Baseline characteristics of participants in the CIMBA consortium with genotype information

From: Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers

Variable

Ovarian cancer cases, N = 2923

Non-cases, N = 19,665

P valueb

Mutation carrier status

  

<0.0001

 BRCA1

2319 (79.3)

12,357 (62.8)

 

 BRCA2

604 (20.7)

7308 (37.2)

 

Year of birth, median (IQR)

1948 (1940, 1955)

1960 (1951, 1969)

<0.0001

Age at diagnosis or censoring, years (mean ± SD)

52.5 ± 9.8

44.7 ± 12.4

<0.0001

Ethnicity, n (%)

  

0.07

  Caucasian, not otherwise specified

2060 (89.7)

13,613 (88.4)

 

  Ashkenazi Jewish

237 (10.3)

1780 (11.6)

 

Height in cm, n

784

6873

 

  Mean ± SD

163.2 ± 6.5

164.8 ± 6.9

<0.0001

  Weight at baselinea in kg, n

780

6789

 

  Mean ± SD

69.0 ± 14.6

68.5 ± 14.1

0.32

Body mass index at baselinea in kg/m2, n

772

6744

 

 Mean ± SD

25.9 ± 5.3

25.2 ± 5.1

0.0002

Weight in early adulthood in kg, n

536

4,912

 

  Mean ± SD

56.5 ± 8.3

57.9 ± 9.5

0.0007

Body mass index in early adulthood in kg/m2, n

536

4881

 

  Mean ± SD

21.2 ± 3.0

21.3 ± 3.3

0.43

Age at menarche in years, n

771

6688

 

  Mean ± SD

13.0 ± 1.5

13.0 ± 1.5

0.90

Parous, n (%)

  

<0.0001

  Yes

805 (88.3)

5790 (77.4)

 

  No

107 (11.7)

1692 (22.6)

 

Age at first live birth in years, n

735

5555

 

  Mean ± SD

24.4 ± 4.5

25.4 ± 4.9

<0.0001

Menopausal status, n (%)

  

<0.0001

  Premenopausal

112 (11.5)

3816 (51.1)

 

  Postmenopausal

863 (88.5)

3654 (48.9)

 

Age at menopause, years (mean ± SD)

46.8 ± 5.7

44.7 ± 6.1

<0.0001

Tumour behaviour, n (%)

  Invasive

1228 (99.2)

  

  Borderline

10 (0.8)

  

Tumour histotype, n (%)

  Serous

892 (67.9)

  

  Mucinous

20 (1.5)

  

 Endometrioid

141 (10.7)

  

  Clear cell

17 (1.3)

  

  Other

243 (18.5)

  

Tumour grade, n (%)

  Well differentiated

43 (4.6)

  

  Moderately differentiated

196 (21.0)

  

  Poorly/undifferentiated

696 (74.4)

  

Tumour stage, n (%)

  Borderline

2 (0.3)

  

  Stage 1

121 (16.4)

  

  Stage 2

93 (12.6)

  

  Stage 3

412 (55.7)

  

  Stage 4

112 (15.1)

  
  1. CIMBA Consortium of Investigators for the Modifiers of BRCA1/2, IQR interquartile range, SD standard deviation
  2. aReported at the date of questionnaire
  3. bP values for comparing cases and non-cases were calculated from logistic regression models with robust sandwich variance estimator
Back to article page